News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
276,264 Results
Type
Article (14665)
Company Profile (290)
Press Release (261301)
Multimedia
Podcasts (66)
Webinars (11)
Section
Business (79748)
Career Advice (157)
Deals (13290)
Drug Delivery (38)
Drug Development (50613)
Employer Resources (31)
FDA (5796)
Job Trends (5159)
News (144881)
Policy (10071)
Tag
Academia (920)
Accelerated approval (9)
Adcomms (14)
Allergies (67)
Alliances (21770)
ALS (98)
Alzheimer's disease (962)
Antibody-drug conjugate (ADC) (164)
Approvals (5882)
Artificial intelligence (193)
Autoimmune disease (52)
Automation (9)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (73)
Biotechnology (231)
Bladder cancer (82)
Brain cancer (34)
Breast cancer (254)
Cancer (2399)
Cardiovascular disease (184)
Career advice (141)
Career pathing (4)
CAR-T (169)
CDC (5)
Cell therapy (458)
Cervical cancer (11)
Clinical research (42540)
Collaboration (848)
Company closure (2)
Compensation (462)
Complete response letters (31)
COVID-19 (1082)
CRISPR (73)
C-suite (365)
Cystic fibrosis (97)
Data (2987)
Denatured (13)
Depression (67)
Diabetes (212)
Diagnostics (1341)
Digital health (7)
Diversity (4)
Diversity, equity & inclusion (9)
Drug discovery (131)
Drug pricing (38)
Drug shortages (3)
Duchenne muscular dystrophy (179)
Earnings (30983)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (50385)
Executive appointments (590)
FDA (7114)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (13)
Funding (768)
Gene editing (145)
Generative AI (14)
Gene therapy (394)
GLP-1 (451)
Government (1123)
Grass and pollen (2)
Guidances (146)
Healthcare (6608)
HIV (12)
Huntington's disease (33)
IgA nephropathy (52)
Immunology and inflammation (150)
Immuno-oncology (9)
Indications (34)
Infectious disease (1167)
Inflammatory bowel disease (140)
Inflation Reduction Act (9)
Influenza (31)
Intellectual property (127)
Interviews (18)
IPO (7326)
IRA (12)
Job creations (868)
Job search strategy (129)
Kidney cancer (8)
Labor market (17)
Layoffs (236)
Leadership (7)
Legal (1398)
Liver cancer (38)
Longevity (8)
Lung cancer (352)
Lymphoma (168)
Machine learning (18)
Management (7)
Manufacturing (270)
MASH (103)
Medical device (2628)
Medtech (2633)
Mergers & acquisitions (6463)
Metabolic disorders (580)
Multiple sclerosis (85)
NASH (13)
Neurodegenerative disease (142)
Neuropsychiatric disorders (45)
Neuroscience (1669)
NextGen: Class of 2025 (2021)
Non-profit (858)
Now hiring (27)
Obesity (258)
Opinion (114)
Ovarian cancer (105)
Pain (75)
Pancreatic cancer (111)
Parkinson's disease (181)
Partnered (10)
Patents (236)
Patient recruitment (205)
Peanut (40)
People (26239)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (15032)
Phase II (19773)
Phase III (12500)
Pipeline (1682)
Policy (78)
Postmarket research (854)
Preclinical (6367)
Press Release (30)
Prostate cancer (116)
Psychedelics (47)
Radiopharmaceuticals (222)
Rare diseases (459)
Real estate (1439)
Recruiting (12)
Regulatory (9317)
Reports (19)
Research institute (951)
Resumes & cover letters (18)
Rett syndrome (13)
RNA editing (15)
RSV (14)
Schizophrenia (104)
Series A (141)
Series B (104)
Service/supplier (1)
Sickle cell disease (57)
Special edition (16)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1993)
State (1)
Stomach cancer (5)
Supply chain (28)
Tariffs (17)
The Weekly (52)
Vaccines (297)
Venture capital (44)
Weight loss (145)
Women's health (19)
Worklife (2)
Date
Today (98)
Last 7 days (388)
Last 30 days (1331)
Last 365 days (18308)
2025 (14318)
2024 (20561)
2023 (22416)
2022 (26825)
2021 (27818)
2020 (23368)
2019 (16235)
2018 (11746)
2017 (13755)
2016 (11854)
2015 (14353)
2014 (10396)
2013 (7490)
2012 (7550)
2011 (7616)
2010 (7430)
Location
Africa (152)
Alabama (58)
Alaska (2)
Arizona (59)
Arkansas (5)
Asia (17857)
Australia (3031)
California (5724)
Canada (1566)
China (588)
Colorado (202)
Connecticut (214)
Delaware (172)
Europe (38401)
Florida (719)
Georgia (178)
Hawaii (2)
Idaho (16)
Illinois (327)
India (22)
Indiana (132)
Iowa (7)
Japan (160)
Kansas (73)
Kentucky (7)
Louisiana (4)
Maine (11)
Maryland (631)
Massachusetts (4562)
Michigan (94)
Minnesota (211)
Mississippi (3)
Missouri (27)
Montana (14)
Nebraska (4)
Nevada (26)
New Hampshire (15)
New Jersey (1398)
New Mexico (12)
New York (1483)
North Carolina (718)
North Dakota (6)
Northern California (2673)
Ohio (149)
Oklahoma (11)
Oregon (22)
Pennsylvania (1069)
Puerto Rico (8)
Rhode Island (25)
South America (210)
South Carolina (6)
Southern California (2238)
Tennessee (32)
Texas (719)
United States (19228)
Utah (79)
Virginia (118)
Washington D.C. (36)
Washington State (486)
West Virginia (1)
Wisconsin (28)
276,264 Results for "kyn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
October 1, 2025
·
3 min read
Press Releases
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 18, 2024
·
3 min read
Drug Development
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
January 4, 2024
·
1 min read
Business
Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced the formation of its distinguished Scientific Advisory Board.
May 29, 2024
·
5 min read
Rare diseases
New Confirmatory Study Hints at ‘Alignment’ Between Applied Therapeutics, FDA for Rare Disease Drug
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Thursday, means it has indeed aligned with the FDA on govorestat’s development.
September 29, 2025
·
2 min read
·
Tristan Manalac
Press Releases
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
September 23, 2025
·
9 min read
Press Releases
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 15, 2025
·
4 min read
Genetown
Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth
Kyn Therapeutics, a clinical-stage biotechnology company, today announced it is rebranding to Ikena Oncology.
December 3, 2019
·
5 min read
Press Releases
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 17, 2025
·
6 min read
Press Releases
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
October 2, 2025
·
6 min read
1 of 27,627
Next
